Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort

Table 3 Simulated medical costs and life-day gained of overall treatment pathway for DLBCL (n = 4880)

	N	5-year time horizon		N	15-year time horizon		N	Lifetime horizon
	N	Cost (£), mean (95 % CI)	Life-days, mean (95 % CI)	N	Cost (£), mean (95 % CI)	Life-days, mean (95 % CI)	N	Cost (£), mean (95 % CI)	Life-days, mean (95 % CI)
Total	4880	18,096 (18,078–18,114)	1021 (1019–1022)	4880	18,396 (18,377–18,415)	2307 (2304–2310)	4880	18,396 (18,377–18,415)	3667 (3661–3672)
Treated	3892	21,712 (21,692–21,732)	1272 (1271–1273)	3892	22,122 (22,101–22,142)	2884 (2881–2887)	3892	22,122 (22,101–22,142)	4589 (4582–4596)
First-line only	3346	17,994 (17,985–18,003)	1300 (1299–1301)	3316	18,088 (18,078–18,097)	2990 (2987–2994)	3316	18,088 (18,078–18,097)	4718 (4711–4725)
Second-line plus
With ASCT	154	78,273 (78,224–78,322)	1620 (1617–1622)	167	79,131 (79,084–79,178)	3705 (3692–3719)	167	79,131 (79,084–79,178)	6837 (6797–6877)
Without ASCT	392	31,209 (31,168–31,251)	889 (886–892)	409	31,471 (31,430–31,512)	1688 (1680–1696)	409	31,471 (31,430–31,512)	2628 (2610–2646)
Not treated	988	2930 (2918–2942)	30 (29–31)	988	2930 (2918–2942)	30 (29–31)	988	2930 (2918–2942)	30 (29–31)